Physician profile
David K Brown
NPI 1568468825
$4,649.55
in general payments reported to CMS, 2019-2025
30 companies · $619 in 2025
The $619 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $575 · 2021: $732 · 2022: $968 · 2023: $849 · 2024: $575 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $751.80 | 2019-2023 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $728.95 | 2019-2023 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $695.56 | 2019-2025 | |
| Abbvie INC. | $447.85 | 2021-2023 | Qulipta, Rinvoq, Ubrelvy |
| Optinose US, INC. | $348.39 | 2019-2025 | |
| Inspire Medical Systems, INC. | $233.39 | 2024 | Inspire |
| Ars Pharmaceuticals Operations, INC. | $215.96 | 2025 | Neffy |
| Genentech USA, INC. | $127.33 | 2020-2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $124.64 | 2020-2025 | Dupixent |
| Pharming Healthcare, INC. | $123.64 | 2025 | |
| Pfizer INC. | $90.58 | 2019-2023 | |
| Incyte Corporation | $77.71 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $76.93 | 2020-2022 | |
| Amgen INC. | $71.25 | 2019-2023 | Tezspire |
| Allergan, INC. | $65.41 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $62.76 | 2020-2023 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $56.25 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $55.81 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $53.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.68 | 2020-2022 | |
| Kaleo, INC. | $40.88 | 2022-2024 | Auvi-Q |
| Biohaven Pharmaceutical Holding Company LTD. | $27.81 | 2022 | |
| Supernus Pharmaceuticals, INC. | $27.54 | 2020 | |
| Csl Behring | $17.97 | 2023 | Hizentra |
| Shire North American Group INC | $14.90 | 2019 | |
| Alk-Abello, INC | $14.02 | 2021 | |
| Blueprint Medicines Corporation | $13.91 | 2023 | Ayvakit |
| Biocryst US Sales Co., LLC | $13.44 | 2021 | |
| Leo Pharma INC. | $13.06 | 2022 | |
| Bio Products Laboratory USA, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.